Jun. 17 at 3:01 PM
$LSTA As of March 31, 2025, Lisata has
$25.8 million in cash with no debt, projected to fund operations through Q4 2026. This runway reduces near-term dilution risk, a positive factor for a clinical-stage company.
Lisata Therapeutics appears potentially undervalued based on its cash reserves, analyst price targets, and clinical pipeline potential, particularly if certepetide achieves regulatory milestones. The company’s market cap (
$13.80–
$16.90 million) is lower than its cash position (
$25.8 million), suggesting the market assigns limited value to its pipeline, which could be a buying opportunity if trials succeed....glta
